Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan-binding

Subendothelial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins drives atherosclerotic arterial disease. In peripheral interstitial fluid from patients with type 2 diabetes (T2D), levels of such particles have been shown to be paradoxically reduced relative to those in serum, presumably reflecting their increased retention within the arterial wall. To identify possible mechanisms involved in lipoprotein retention in T2D, we obtained serum and skin blister fluid from such patients and matched controls, together with skin biopsies in a subset of individuals. In T2D, smaller LDL and VLDL remnant particles were more prominent in serum, but not in interstitial fluid, reflecting their enhanced vascular entrapment. The interstitial-fluid-to-serum ratio of apolipoprotein-B was 58% lower in T2D than in controls (0.14 vs 0.33), concomitant with increased susceptibility for LDL binding to proteoglycans. The most marked differences were seen in patients with clinically evident cardiovascular disease. The degree of transvascular retention was positively related to the propensity of isolated serum LDL to bind aortic proteoglycans, both in T2D and in controls. Skin unesterified cholesterol levels were higher in T2D patients relative to healthy controls. With aging, both proteoglycan binding and apparent vascular retention of LDL increased in controls, but not in T2D, indicating that these mechanisms may also be relevant for atherogenesis in non-diabetic individuals.

Authors

Institutions

Publication Details

Journal
JCI Insight
Published
2026-04-07
DOI
https://doi.org/10.1172/jci.insight.177849
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan-binding

Jennifer Härdfeldt, Lauri Äikäs, Minna Holopainen, Katariina Öörni et al.
JCI Insight
Diabetes, Cardiovascular Risks, and Lipoproteins
article

Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan-binding

Jennifer Härdfeldt, Lauri Äikäs, Minna Holopainen, Katariina Öörni, Sara Straniero, Par Bjorklund, Mats J. Rudling, Bo Angelin
article en

Abstract

Subendothelial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins drives atherosclerotic arterial disease. In peripheral interstitial fluid from patients with type 2 diabetes (T2D), levels of such particles have been shown to be paradoxically reduced relative to those in serum, presumably reflecting their increased retention within the arterial wall. To identify possible mechanisms involved in lipoprotein retention in T2D, we obtained serum and skin blister fluid from such patients and matched controls, together with skin biopsies in a subset of individuals. In T2D, smaller LDL and VLDL remnant particles were more prominent in serum, but not in interstitial fluid, reflecting their enhanced vascular entrapment. The interstitial-fluid-to-serum ratio of apolipoprotein-B was 58% lower in T2D than in controls (0.14 vs 0.33), concomitant with increased susceptibility for LDL binding to proteoglycans. The most marked differences were seen in patients with clinically evident cardiovascular disease. The degree of transvascular retention was positively related to the propensity of isolated serum LDL to bind aortic proteoglycans, both in T2D and in controls. Skin unesterified cholesterol levels were higher in T2D patients relative to healthy controls. With aging, both proteoglycan binding and apparent vascular retention of LDL increased in controls, but not in T2D, indicating that these mechanisms may also be relevant for atherogenesis in non-diabetic individuals.

JCI Insight
University of Helsinki (FI), Karolinska Institutet (SE), Wihuri Research Institute (FI)
AstraZeneca, Foundation for Cardiovascular Research, Aarne Koskelon Säätiö, Academy of Finland, Kommunfullmäktige, Stockholms Stad, Hjärt-Lungfonden, Karolinska Institutet, Knut och Alice Wallenbergs Stiftelse, Novo Nordisk, Vetenskapsrådet, Sydäntutkimussäätiö, Sigrid Juséliuksen Säätiö, Novo Nordisk Fonden, Ipsen, Center for Innovative Medicine
Good health and well-being
Openalex Percentile: Top 21%
Diabetes, Cardiovascular Risks, and Lipoproteins
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.